Patent First, Launch Faster: How Pharma Companies Align IP Filing with Commercialization to Win Market Share
Every year, drug companies leave hundreds of millions of dollars on the table. Not because their molecules fail, not because […]
Don’t Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in M&A Due Diligence
When Pfizer paid $11.6 billion for Array BioPharma in 2019, analysts praised the deal’s logic. Two years later, generic manufacturers
Don’t Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in M&A Due Diligence Read Post »
Beyond 20 Years: What Actually Determines a Drug’s Market Exclusivity
Ask anyone in pharma how long a drug patent lasts and they’ll say 20 years. The number is technically correct
Beyond 20 Years: What Actually Determines a Drug’s Market Exclusivity Read Post »
The Four Exclusivities Behind Every Pharma Mega-Deal
When a buyer writes a $74 billion check for a drugmaker, they are not paying for the molecule. They are
The Four Exclusivities Behind Every Pharma Mega-Deal Read Post »
Post-Approval Patents: The Hidden LOE Risk Map
Most pharmaceutical IP work gets framed as a pre-approval problem. File the composition patent during discovery, secure the use claims
Post-Approval Patents: The Hidden LOE Risk Map Read Post »
Patent Cliff Forecasting: How to Predict Drug Price Erosion Before It Happens
The most expensive number in pharmaceutical finance is the one nobody on the executive team wants to commit to: how
Patent Cliff Forecasting: How to Predict Drug Price Erosion Before It Happens Read Post »
Post-Approval Patent Strategy: How to Protect Your Drug from Regulatory and IP Risk After Approval
Every time a pharmaceutical company changes something about an approved drug, it opens two doors simultaneously. The first leads to
Pharma Patent Strategy: How to Defend Exclusivity Without Getting Sued
The pharmaceutical industry has a math problem. A blockbuster drug throws off cash at a rate that makes any other
Pharma Patent Strategy: How to Defend Exclusivity Without Getting Sued Read Post »
From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff
A composition of matter patent is the only piece of pharmaceutical intellectual property that a generic or biosimilar manufacturer cannot
From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff Read Post »
